JSA advised Felix Pharmaceuticals in connection with a USD 175 million investment by Advent International, a leading global private equity firm, for acquiring a significant minority stake in the company
Founded in 2015 and headquartered in Dublin, Felix Pharmaceuticals develops and manufactures generic (off-patent) medicines for companion animals such as dogs, cats, and horses. The company boasts one of the industry’s broadest product portfolios, including 14 U.S. FDA-approved drugs, with a robust pipeline under development. Felix supplies these products under private labels and is one of the fastest-growing players in the global animal health space.
Also Read: Trilegal Advising Mahindra & Mahindra Financial Services: Landmark ₹2,996 Cr Rights Deal
The JSA team advising Felix was led by Sidharrth Shankar (Partner), with support from Prakriti Jaiswal (Partner), Anindita Basu (Principal Associate), Rishika Agarwal (Senior Associate), Eksha Narayan (Senior Associate), and Jatin Oberoi (Senior Associate).
Founded in 1991, JSA Advocates and Solicitors is one of India’s leading full-service national law firms with over 600 legal professionals spread across its seven locations in the country – Ahmedabad, Bengaluru, Chennai, Gurugram, Hyderabad, Mumbai and New Delhi. As the go-to firm for the new transformative and digital Indian economy, JSA is regularly involved in many of the first-to-market and complex transactions and plays an integral role in advocacy and policy matters impacting various industries. JSA has built a reputation for its client-centric approach, quality of service, domain knowledge and insights across sectors and for delivering innovative solutions to complex legal and commercial issues for the benefit of clients. Consequently, JSA has consistently been recognised as a top-tier firm for its capabilities and expertise across practices and sectors by leading legal directories, league tables and industry journals.
Read More: BAT’s $1.4B ITC Stake Sale, SAM, AZB, HSF & Ashurst Act as Legal Advisors
